Belzutifan Combo Could be Second-Line Option in Advanced RCC

Published Date: 04 Mar 2026

Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.

Read Full News

Latest News

Liquid Biopsies Cut EBV Burkitt Lymphoma Time to Diagnosis

Broader implementation would require substantial investment, but long-term dividends of liquid biopsy analysis in the region could affect diagnosis and care of much more than just this cancer.

Can Exercise Extend Survival After Breast Cancer?

A ‘target trial’ emulation study suggests that regular exercise can help breast cancer survivors live longer.

PSA Screening Overdiagnosis Rises Sharply With Age

About one third of cancers detected by PSA screening at age 70, and more than half at age 80, are unlikely to become clinically meaningful within 15 years.

High Fruit, Veggie Diet Tied to Early-Onset Lung Cancer?

Counterintuitive findings hint that diets rich in fruit, vegetables, and whole grains may increase the risk of lung cancer in young nonsmokers, but experts are skeptical.

Can Alternating Venetoclax Regimens Improve AML Outcomes?

A phase 2 study investigates the combination of cladribine plus low-dose cytarabine and venetoclax alternating with azacitidine plus venetoclax for newly diagnosed acute myeloid leukemia.

Photopenia on [18F]FDG PET/CT Predicts Benign Renal Lesions

Photopenia in high CT density renal lesions on [18F]FDG PET/CT scans shows a high negative predictive value for excluding malignancy.

Todays Updates

Baveno Criteria May Reduce Endoscopy Burden in Cirrhosis

The Baveno VI criteria show high sensitivity for ruling out clinically significant portal hypertension and high-risk varices in patients with cirrhosis.

Todays Updates

Baveno Criteria May Reduce Endoscopy Burden in Cirrhosis

The Baveno VI criteria show high sensitivity for ruling out clinically significant portal hypertension and high-risk varices in patients with cirrhosis.

Latest News

Broader implementation would require substantial investment, but long-term dividends of liquid biopsy analysis in the region could affect diagnosis and care of much more than just this cancer.

A ‘target trial’ emulation study suggests that regular exercise can help breast cancer survivors live longer.

About one third of cancers detected by PSA screening at age 70, and more than half at age 80, are unlikely to become clinically meaningful within 15 years.

Counterintuitive findings hint that diets rich in fruit, vegetables, and whole grains may increase the risk of lung cancer in young nonsmokers, but experts are skeptical.

A phase 2 study investigates the combination of cladribine plus low-dose cytarabine and venetoclax alternating with azacitidine plus venetoclax for newly diagnosed acute myeloid leukemia.

Photopenia in high CT density renal lesions on [18F]FDG PET/CT scans shows a high negative predictive value for excluding malignancy.

News All Time

Is Vitamin D a Key to Better Breast Cancer Survival?

A prospective study links sufficient vitamin D levels at the time of breast cancer diagnosis to improved overall survival.

Where Does Mistletoe Extract Fit in Supportive Cancer Care?

Mistletoe therapy may improve the QOL of patients with cancer; however, evidence does not support a survival benefit, limiting its role in routine oncology care.

A Chemo-Free Option for Some Advanced Endometrial Cancers?

A phase 2 study suggests that immunotherapy plus radiation could spare some patients with advanced endometrial cancer from chemotherapy.

Early Tislelizumab May Boost PFS in Esophageal Cancer

For patients with locally advanced esophageal cancer, front-loading immunotherapy with induction chemo and chemoradiotherapy, without maintenance immunotherapy, may improve outcomes.

ctDNA Predicts Relapse in Locally Advanced Cervical Cancer

Posttreatment ctDNA positivity correlates with worse relapse-free survival and earlier recurrence in patients with locally advanced cervical cancer, real-world data show.

GLP-1 RAs May Lower Hysterectomy Risk in Endometrial Cancer

There’s now a hint that GLP-1 receptor agonists might prevent hysterectomies in endometrial intraepithelial neoplasia/early-stage endometrial cancer, but prospective trials are needed to confirm it.

Infection Burden High With Myeloma T-Cell Therapies

A retrospective study suggests a high burden of prolonged, mostly low-grade infections in patients with multiple myeloma who receive T-cell-engaging therapies.

Weight-Based and Fixed-Dose Pembrolizumab Compared in NSCLC

A national cohort study compares the safety and efficacy of weight-based and fixed-dose pembrolizumab regimens in patients with advanced non-small cell lung cancer.

HER2 ADC Shows Promise in Recurrent Endometrial Cancer

Trastuzumab pamirtecan, a HER2-targeted antibody-drug conjugate, achieved ‘exceptional’ antitumor responses in patients with recurrent endometrial cancer, especially those with HER2 IHC 3+ tumors.

ctDNA-Guided Adjuvant Therapy Cuts Bladder Cancer Costs

Researchers evaluate whether postoperative ctDNA-guided adjuvant atezolizumab after radical cystectomy is cost-effective compared with standard care in patients with muscle-invasive bladder cancer.

PSA Often Unchanged With Enzalutamide Progression

A stable PSA level does not rule out progression in men taking enzalutamide for advanced prostate cancer.

Assisted Dying Under Scrutiny From Medscape's Readers

Comments on a Medscape feature push past ideology to ask what evidence, oversight, and safeguards should be available for patients who choose assisted death.

Chemotherapy Boosts Survival for Older Patients With TNBC

Patients aged 70 years or older stand to benefit from adjuvant chemotherapy for triple-negative breast cancer, but the majority do not receive it.

Radioligand Therapy Set to Transform Oncology Care

Nearly 400 trials and Belgium’s isotope hub signal rapid clinical diversification for radioligand therapy — but policy, funding, and system readiness must follow.

Venetoclax Combo Shows Promise in Younger Patients With AML

Researchers conducted a systematic review and meta-analysis for studies of acute myeloid leukemia patients with a median age less than 70 treated with HMA plus venetoclax.

Gotistobart Response Rate Bests Chemo in Pretreated NSCLC

Previously treated patients with NSCLC respond to anti-CTLA-4 therapy.

Recommended News For You

New guidelines expand access to lung cancer screening, but gaps remain in reaching rural and uninsured populations

High Fruit, Veggie Diet Tied to Early-Onset Lung Cancer?

A garden can save your life

Year in Review: Chronic Lymphocytic Leukemia

Video: Liver transplant for patients with advanced colorectal cancer

FDA Approves New Drug Combo for RR Multiple Myeloma

High weight and obesity are associated with poor outcomes in leukemia treatment.

Recommended Articles For You

MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed 

Unveiling the Mystery of Echinocyte: A Closer Look at the Unique Red Blood Cell 

Paving the Path to Precision: A Review of TAR-200 in the Evolving Bladder Cancer Landscape 

Unlocking the Secrets of Hemoglobin: Exploring the Wonders of Life-Sustaining Iron Compounds 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Maintenance Rituximab Improves Survival in Elderly MRD-Negative MCL Patients.

2.

New PET tracer enables same-day imaging of triple-negative breast and urothelial cancers

3.

Intractable cancers may respond better to treatment when using new radiation and high-performance computing.

4.

In Higher-Risk MDS, CMML, All-Oral Therapy Has Promise.

5.

improvements in the treatment of prostate cancer resistant to chemotherapy.

1.

Exploring Digital Cognitive Stimulation for Elderly Breast Cancer Patients

2.

Survival Rate Dynamics in Hematologic and Solid Malignancies

3.

Essential Oncology Updates: Diagnosis, Treatment Advances, Tools & Education Resources

4.

Epigenetics and Resistance: Mechanisms in Histone Methylation-Targeted Therapies

5.

Cowden Syndrome and Cancer: Understanding the Risk Factors 

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II

2.

Efficient Management of First line ALK-rearranged NSCLC - Part VII

3.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part IV

4.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI

5.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot